ArticleF&S reports2025
Impact of follicle size before luteal progesterone supplementation on clinical outcomes of modified natural cycle single frozen embryo transfer.
Article in F&S reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Follicle Size at Trigger on Reproductive Outcomes in Letrozole-Modified Natural Frozen Embryo Transfer Cycles in High Responder Patients.Journal of assisted reproduction and genetics · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Objective: To determine whether follicle size at midcycle transvaginal sonography imaging before luteal progesterone supplementation predicts modified natural cycle single frozen embryo transfer (mNC-SFET) outcomes. Design: Retrospective chart review. Subjects: Frozen embryo transfer charts were reviewed. After inclusion and exclusion criteria were applied, data were abstracted from cases of mNC-SFET (n = 115). Exposure: For group A, lead follicle measuring <16 mm on day of trigger or peak +ovulation predictor kit (n = 50), and for group B, lead follicle measuring ≥16 mm on day of trigger or peak +ovulation predictor kit (n = 65). Main Outcome Measures: Follicle size analyzed as possible predictor of primary outcome ongoing pregnancy rate (OPR) as well as secondary outcomes implantation rate (IR), clinical pregnancy rate (CPR), and spontaneous abortion (SAB) rate via bivariate associations and multivariate logistic regression analyses. Results: Bivariate analyses showed no differences between groups in OPR (A, 48.0%, 24/50, and B, 44.6 %, 29/65), IR (A, 64.0%, 32/50, and B, 61.5%, 40/65), CPR (A, 58.0%, 29/50, and B, 52.3%, 34/65), and SAB rates (A, 25.0%, 8/32, and B, 27.5%, 11/40). Multivariate analysis to investigate potential confounding between lead follicle size and outcomes of interest showed no difference in the primary and secondary outcomes. Furthermore, multivariate analyses using lead follicle size as a continuous variable showed no difference in outcomes. Conclusion: In normo-ovulatory women undergoing mNC-SFET with natural endometrial preparation with human chorionic gonadotropin trigger or luteinizing hormone surge to time frozen embryo transfer, lead follicle size before luteal phase supplementation does not impact clinical outcomes such as IR, CPR, SAB rate, or OPR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.